Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 11, 2014, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $337.00 to $15,638,127.00.

Highlighted Stocks Traded by Insiders:

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C, who is Chairman and CEO at Jazz Pharmaceuticals, sold 5,000 shares at $178.79 on Dec. 11, 2014. Following this transaction, the Chairman and CEO owned 559,131 shares meaning that the stake was reduced by 0.89% with the 5,000-share transaction.

The shares most recently traded at $173.21, down $5.58, or 3.22% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,598
  • 12-Week # shares sold: 70,964
  • 24-Week # shares sold: 150,413

The average volume for Jazz Pharmaceuticals has been 785,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $10.8 billion and is part of the health care sector and drugs industry. Shares are up 38.62% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 356.4. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexandria Real Estate Equities (ARE) - FREE Research Report

Marcus Joel S, who is Chief Executive Officer at Alexandria Real Estate Equities, sold 4,000 shares at $91.19 on Dec. 11, 2014. Following this transaction, the Chief Executive Officer owned 586,291 shares meaning that the stake was reduced by 0.68% with the 4,000-share transaction.

Richardson Stephen, who is Chief Operating Officer at Alexandria Real Estate Equities, sold 5,000 shares at $90.01 on Dec. 11, 2014. Following this transaction, the Chief Operating Officer owned 72,007 shares meaning that the stake was reduced by 6.49% with the 5,000-share transaction.

The shares most recently traded at $89.15, down $0.86, or 0.97% since the insider transaction. Historical insider transactions for Alexandria Real Estate Equities go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 24,666
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 47,583

The average volume for Alexandria Real Estate Equities has been 498,100 shares per day over the past 30 days. Alexandria Real Estate Equities has a market cap of $6.5 billion and is part of the financial sector and real estate industry. Shares are up 39.85% year-to-date as of the close of trading on Wednesday.

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. The stock currently has a dividend yield of 3.28%. The company has a P/E ratio of 50.7. Currently, there are 3 analysts who rate Alexandria Real Estate Equities a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARE - FREE

TheStreet Quant Ratings rates Alexandria Real Estate Equities as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Alexandria Real Estate Equities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SciClone Pharmaceuticals (SCLN) - FREE Research Report

Hawkins Richard J, who is Director at SciClone Pharmaceuticals, sold 15,591 shares at $8.80 on Dec. 11, 2014. Following this transaction, the Director owned 34,409 shares meaning that the stake was reduced by 31.18% with the 15,591-share transaction.

The shares most recently traded at $8.55, down $0.25, or 2.88% since the insider transaction.

The average volume for SciClone Pharmaceuticals has been 572,000 shares per day over the past 30 days. SciClone Pharmaceuticals has a market cap of $457.0 million and is part of the health care sector and drugs industry. Shares are up 78.57% year-to-date as of the close of trading on Wednesday.

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for the treatment of oncology, infectious diseases, and cardiovascular disorders primarily in the People's Republic of China. The company has a P/E ratio of 21.9. Currently, there are no analysts who rate SciClone Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCLN - FREE

TheStreet Quant Ratings rates SciClone Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full SciClone Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null